FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297874867> ?p ?o ?g. }

• W4297874867 endingPage "6161" @default.
• W4297874867 startingPage "6151" @default.
• W4297874867 abstract "Abstract Clonal hematopoiesis of indeterminate potential (CHIP), an emerging biomarker for personalized risk-directed interventions, is increased in cancer survivors. However, little is known about patient preferences for CHIP testing. We surveyed participants in a prospective cohort study of young women with breast cancer (BC). The emailed survey included an introduction to CHIP and a vignette eliciting participants’ preferences for CHIP testing, considering sequentially: population-based 10-year risk of BC recurrence, hematologic malignancy, and heart disease; increased CHIP-associated risks; current CHIP management; dedicated CHIP clinic; and hypothetical CHIP treatment. Preference changes were evaluated using the McNemar test. The survey response rate was 82.2% (528/642). Median age at time of survey was 46 years and median time from diagnosis was 108 months. Only 5.9% had prior knowledge of CHIP. After vignette presentation, most survivors (87.1%) recommended CHIP testing for the vignette patient. Presented next with CHIP-independent, population-based risks, 11.1% shifted their preference from testing to not testing. After receiving information about CHIP-associated risks, an additional 10.1% shifted their preference to testing. Preference for testing increased if vignette patient was offered a CHIP clinic or hypothetical CHIP treatment, with 7.2% and 14.1% switching preferences toward testing, respectively. Finally, 75.8% of participants desired CHIP testing for themselves. Among participants, 28.2% reported that learning about CHIP caused at least moderate anxiety. Most young survivors favored CHIP testing, with preferences influenced by risk presentation and potential management strategies. Our findings highlight the importance of risk communication and psychosocial support when considering biomarkers for future risk in cancer survivors. This trial has been registered at www.clinicaltrials.gov as #NCT01468246." @default.
• W4297874867 created "2022-10-01" @default.
• W4297874867 creator A5001562050 @default.
• W4297874867 creator A5003947352 @default.
• W4297874867 creator A5010429902 @default.
• W4297874867 creator A5022943610 @default.
• W4297874867 creator A5024392666 @default.
• W4297874867 creator A5027044033 @default.
• W4297874867 creator A5027326315 @default.
• W4297874867 creator A5032396015 @default.
• W4297874867 creator A5034830236 @default.
• W4297874867 creator A5039694693 @default.
• W4297874867 creator A5050468541 @default.
• W4297874867 creator A5058699521 @default.
• W4297874867 creator A5060188343 @default.
• W4297874867 creator A5064031188 @default.
• W4297874867 creator A5070668676 @default.
• W4297874867 creator A5090425082 @default.
• W4297874867 creator A5025041221 @default.
• W4297874867 date "2022-12-27" @default.
• W4297874867 modified "2023-10-15" @default.
• W4297874867 title "Patient perspectives on testing for clonal hematopoiesis of indeterminate potential" @default.
• W4297874867 cites W1928369134 @default.
• W4297874867 cites W1972142948 @default.
• W4297874867 cites W1977610165 @default.
• W4297874867 cites W1985823023 @default.
• W4297874867 cites W1997688570 @default.
• W4297874867 cites W2044053813 @default.
• W4297874867 cites W2056008497 @default.
• W4297874867 cites W2065341753 @default.
• W4297874867 cites W2073543491 @default.
• W4297874867 cites W2091483668 @default.
• W4297874867 cites W2099610303 @default.
• W4297874867 cites W2108406644 @default.
• W4297874867 cites W2115854814 @default.
• W4297874867 cites W2126816979 @default.
• W4297874867 cites W2143558286 @default.
• W4297874867 cites W2148748617 @default.
• W4297874867 cites W2149858388 @default.
• W4297874867 cites W2206147655 @default.
• W4297874867 cites W2297062822 @default.
• W4297874867 cites W2574119868 @default.
• W4297874867 cites W2598922425 @default.
• W4297874867 cites W2619042849 @default.
• W4297874867 cites W2628145035 @default.
• W4297874867 cites W2651631686 @default.
• W4297874867 cites W2745259295 @default.
• W4297874867 cites W2790993647 @default.
• W4297874867 cites W2794112085 @default.
• W4297874867 cites W2802363130 @default.
• W4297874867 cites W2804449597 @default.
• W4297874867 cites W2899732591 @default.
• W4297874867 cites W2900081888 @default.
• W4297874867 cites W2955871436 @default.
• W4297874867 cites W2963903719 @default.
• W4297874867 cites W3000627318 @default.
• W4297874867 cites W3003299879 @default.
• W4297874867 cites W3011823578 @default.
• W4297874867 cites W3021383594 @default.
• W4297874867 cites W3023393728 @default.
• W4297874867 cites W3033156498 @default.
• W4297874867 cites W3035391567 @default.
• W4297874867 cites W3046447639 @default.
• W4297874867 cites W3093490071 @default.
• W4297874867 cites W3108635861 @default.
• W4297874867 cites W3171701178 @default.
• W4297874867 cites W3208938232 @default.
• W4297874867 cites W4205850975 @default.
• W4297874867 cites W4220661260 @default.
• W4297874867 cites W4229460511 @default.
• W4297874867 doi "https://doi.org/10.1182/bloodadvances.2022008376" @default.
• W4297874867 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36129839" @default.
• W4297874867 hasPublicationYear "2022" @default.
• W4297874867 type Work @default.
• W4297874867 citedByCount "1" @default.
• W4297874867 countsByYear W42978748672023 @default.
• W4297874867 crossrefType "journal-article" @default.
• W4297874867 hasAuthorship W4297874867A5001562050 @default.
• W4297874867 hasAuthorship W4297874867A5003947352 @default.
• W4297874867 hasAuthorship W4297874867A5010429902 @default.
• W4297874867 hasAuthorship W4297874867A5022943610 @default.
• W4297874867 hasAuthorship W4297874867A5024392666 @default.
• W4297874867 hasAuthorship W4297874867A5025041221 @default.
• W4297874867 hasAuthorship W4297874867A5027044033 @default.
• W4297874867 hasAuthorship W4297874867A5027326315 @default.
• W4297874867 hasAuthorship W4297874867A5032396015 @default.
• W4297874867 hasAuthorship W4297874867A5034830236 @default.
• W4297874867 hasAuthorship W4297874867A5039694693 @default.
• W4297874867 hasAuthorship W4297874867A5050468541 @default.
• W4297874867 hasAuthorship W4297874867A5058699521 @default.
• W4297874867 hasAuthorship W4297874867A5060188343 @default.
• W4297874867 hasAuthorship W4297874867A5064031188 @default.
• W4297874867 hasAuthorship W4297874867A5070668676 @default.
• W4297874867 hasAuthorship W4297874867A5090425082 @default.
• W4297874867 hasBestOaLocation W42978748671 @default.
• W4297874867 hasConcept C15744967 @default.
• W4297874867 hasConcept C2908647359 @default.
• W4297874867 hasConcept C71924100 @default.

• next